Jeremy Herrmann, MD was awarded a two-year grant from the Zoll Foundation to study the response and efficacy of acute administration of the novel neuroprotective cold stress hormone Fibroblast Growth Factor 21 (FGF21) in rat pediatric asphyxial cardiac arrest.
In addition, he received a one-year grant from the Laerdal Foundation for Acute Medicine to study the impact of using sustained administration of this therapy. These projects are mentored by Drs. Patrick Kochanek (Safar Center Director) and Travis Jackson (Associate Professor of Molecular Physiology and Pharmacology at the University of South Florida) who are collaborating on a series of linked studies targeting strategies to improve the efficacy of therapeutic hypothermia in models of acute brain injury and in patients.
These two grants will support Dr. Herrmann’s work in this exciting area of research. His goal is to test if FGF21 and hypothermia act synergistically to improve neurologic outcome, and to optimize the dosing regimen of this new potential combination therapy. Dr. Herrmann is funded by the National Institute of Child Health and Human Development as a T32 Scholar. We are grateful to both the Zoll and Laerdal Foundations for their generous support.